NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT05548348: First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation |
|
|
| Recruiting | 2 | 30 | RoW | Furmonertinib 160 mg, Q.D., AST2818 160 mg, Q.D. | Chongqing University Cancer Hospital, Army Specialty Medical Center, The Second Affilicated Hospital of Chongqing Medical University | Non-small Cell Lung Cancer, EGFR G719X, EGFR L861Q, EGFR S768I | 12/23 | 10/25 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |